SOPHiA GENETICS, a leader in AI-driven precision medicine, has announced a major expansion in the United States by partnering with two of the largest U.S. healthcare systems. These institutions, which collectively analyze millions of genetic samples annually, will use the SOPHiA DDM™ platform to scale genomic data analysis and enhance precision medicine services. The expansion will initially enable genomic testing for up to 60,000 patients each year, focusing on hereditary cancers and rare diseases across the West Coast and Midwest. This move strengthens SOPHiA GENETICS' presence in the U.S. and supports its mission to democratize data-driven medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NE84695) on February 10, 2026, and is solely responsible for the information contained therein.